Literature DB >> 30878832

Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.

Debasis Das1, Jian Hong2.   

Abstract

The 4-aminoquinazoline core is an interesting pharmacophore and its applications in medicinal chemistry are wide spread. The core has been used for making many kinase inhibitors in past few years. Many researcher demonstrated 4-aminoquinazoline derivatives as specific kinase inhibitors, including tyrosine kinase and serine/theronine kinases. A number of anticancer drugs with 4-aminoquinazoline core are in the market, e.g. gefitinib, erlotinib, afatinib, lapatinib, decomitinib etc. 4-aminoquinazoline derivatives are applied for target specific treatment of lung, breast, colon, prostate cancers. In this review, we discussed the current development of 4-aminoquinazoline derivatives as kinase inhibitors and their uses as anticancer agents in recent years.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aminoquinazoline; Aurora; EGFR; HER; Inhibitor; Kinase; PI3K; Quinazoline; RET; VEGFR

Mesh:

Substances:

Year:  2019        PMID: 30878832     DOI: 10.1016/j.ejmech.2019.03.004

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Treatment of Cancer and Alzheimer's Disease by PROTAC Degradation of EGFR.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2019-07-10       Impact factor: 4.345

2.  Design, synthesis, crystal structure, and in vitro antibacterial activities of sulfonamide derivatives bearing the 4-aminoquinazoline moiety.

Authors:  Suran Wan; Nan Wu; Ya Yan; Yehui Yang; Guangmin Tian; Lian An; Xiaoping Bao
Journal:  Mol Divers       Date:  2022-07-02       Impact factor: 2.943

3.  Efficient Hit-to-Lead Searching of Kinase Inhibitor Chemical Space via Computational Fragment Merging.

Authors:  Grigorii V Andrianov; Wern Juin Gabriel Ong; Ilya Serebriiskii; John Karanicolas
Journal:  J Chem Inf Model       Date:  2021-11-11       Impact factor: 4.956

4.  A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.

Authors:  Shu Wang; Yingshi Zhang; Tianshu Ren; Qiong Wu; Hongyuan Lu; Xiaochun Qin; Yuyan Liu; Huaiwei Ding; Qingchun Zhao
Journal:  Cell Death Dis       Date:  2020-06-30       Impact factor: 8.469

5.  Facile synthetic approach towards vasorelaxant active 4-hydroxyquinazoline-4-carboxamides.

Authors:  Marian N Aziz; Siva S Panda; ElSayed M Shalaby; Nehmedo G Fawzy; Adel S Girgis
Journal:  RSC Adv       Date:  2019-09-10       Impact factor: 3.361

Review 6.  Intrinsically Fluorescent Anti-Cancer Drugs.

Authors:  Md Lutful Kabir; Feng Wang; Andrew H A Clayton
Journal:  Biology (Basel)       Date:  2022-07-28

7.  Platinum(II) Terpyridine Anticancer Complexes Possessing Multiple Mode of DNA Interaction and EGFR Inhibiting Activity.

Authors:  Chaoyang Li; Fengmin Xu; Yao Zhao; Wei Zheng; Wenjuan Zeng; Qun Luo; Zhaoying Wang; Kui Wu; Jun Du; Fuyi Wang
Journal:  Front Chem       Date:  2020-04-28       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.